生产企业：OPKO Health
OPK-88006 is OPKO Health's long-acting GLP-1/glucagon dual agonist peptide — a long-acting analogue of the peptide hormone oxyntomodulin, a naturally occurring GLP-1/glucagon dual agonist. In collaboration with Entera Bio, it is being advanced as an oral GLP-1/glucagon tablet candidate that combines the peptide with Entera's N-Tab oral delivery technology, targeting obesity and metabolic disorders.
OPK-88006 is OPKO Health's long-acting GLP-1/glucagon dual agonist peptide — a long-acting analogue of the peptide hormone oxyntomodulin, a naturally occurring GLP-1/glucagon dual agonist. In collaboration with Entera Bio, it is being advanced as an oral GLP-1/glucagon tablet candidate that combines the peptide with Entera's N-Tab oral delivery technology, targeting obesity and metabolic disorders.
Long-acting GLP-1/glucagon dual agonist; a long-acting analogue of the peptide hormone oxyntomodulin (a naturally occurring GLP-1/glucagon dual agonist).
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
